We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+29.89%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.5B
AUM Growth
+$361M
Cap. Flow
+$95.2M
Cap. Flow %
6.35%
Top 10 Hldgs %
63.32%
Holding
74
New
17
Increased
21
Reduced
30
Closed
4
Avg Time Held Equity + Options
1.4 years
Top 10 Avg Time Held Equity + Options
1.2 years
Top 20 Avg Time Held Equity + Options
1 year
Avg Time Held Equity only
1.5 years
Top 10 Avg Time Held Equity only
1.3 years
Top 20 Avg Time Held Equity only
1.1 years

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$33M
2
RVTY icon
Revvity
RVTY
+$31.9M
3
PFE icon
Pfizer
PFE
+$30.6M
4
VTRS icon
Viatris
VTRS
+$15.9M
5
INSP icon
Inspire Medical Systems
INSP
+$13.6M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$35.6M
2
IMGN icon
Immunogen Inc
IMGN
+$22.2M
3
ARGX icon
argenx
ARGX
+$12.1M
4
ILMN icon
Illumina
ILMN
+$12.1M
5
KRYS icon
Krystal Biotech
KRYS
+$8.65M

Sector Composition

Rank Sector Weight
1 Healthcare 89.26%
2 Miscellaneous 10.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
NTRA icon
1
Natera
NTRA
$58.3B
$163M 10.85%
1,778,051
-473,537
-21% -$35.6M
2022 Q2
7 quarters
GSK icon
2
GSK
GSK
$98.2B
$162M 10.79%
3,771,994
+799,040
+27% +$33M
2018 Q1
24 quarters
QQQ icon
3
PUT
Invesco QQQ Trust
QQQ
$487B
$145M 9.68%
326,800
+176,800
+118% +$75.8M
2023 Q1
4 quarters
INSP icon
4
Inspire Medical Systems
INSP
$2.03B
$90.4M 6.03%
420,699
+69,583
+20% +$13.6M
2023 Q2
3 quarters
TEVA icon
5
Teva Pharmaceutical Industries Limited
TEVA
$47.9B
$85M 5.67%
6,025,169
-129,185
-2% -$1.63M
2020 Q3
14 quarters
VERA icon
6
Vera Therapeutics
VERA
$2.06B
$78.6M 5.25%
1,823,781
-91,049
-5% -$3.24M
2022 Q3
6 quarters
SNDX icon
7
Syndax Pharmaceuticals
SNDX
$1.22B
$74.6M 4.97%
3,133,113
-250,131
-7% -$5.58M
2022 Q2
7 quarters
UTHR icon
8
United Therapeutics
UTHR
$23.2B
$57.7M 3.85%
251,135
+4,901
+2% +$1.11M
2020 Q2
15 quarters
RVTY icon
9
Revvity
RVTY
$17.3B
$50.7M 3.38%
483,160
+300,101
+164% +$31.9M
2021 Q3
10 quarters
TECH icon
10
Bio-Techne
TECH
$11.4B
$42.8M 2.85%
607,687
+142,380
+31% +$10.2M
2022 Q4
5 quarters
HCA icon
11
HCA Healthcare
HCA
$101B
$34.6M 2.31%
103,821
-10,984
-10% -$3.36M
2023 Q1
4 quarters
HQY icon
12
HealthEquity
HQY
$7.65B
$34.4M 2.29%
421,345
-73,574
-15% -$5.74M
2023 Q3
2 quarters
PFE icon
13
Pfizer
PFE
$168B
$30.6M 2.04%
+1,102,042
New +$30.6M
2024 Q1
0 quarters
CLDX icon
14
Celldex Therapeutics
CLDX
$2.27B
$29.8M 1.99%
711,115
-42,992
-6% -$1.77M
2021 Q4
9 quarters
CYH icon
15
Community Health Systems
CYH
$422M
$27.9M 1.86%
7,980,641
+749,515
+10% +$2.53M
2020 Q4
13 quarters
SWAV icon
16
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$26.2M 1.75%
80,555
+4,733
+6% +$1.16M
2023 Q1
4 quarters
ARGX icon
17
argenx
ARGX
$53.2B
$21.5M 1.43%
54,518
-31,314
-36% -$12.1M
2021 Q3
10 quarters
THC icon
18
Tenet Healthcare
THC
$22.2B
$18.5M 1.23%
175,631
-11,634
-6% -$1.05M
2023 Q4
1 quarter
IONS icon
19
Ionis Pharmaceuticals
IONS
$7.33B
$16.3M 1.09%
376,438
+51,784
+16% +$2.47M
2021 Q2
11 quarters
SPY icon
20
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$815B
$15.8M 1.06%
30,300
-89,700
-75% -$44.7M
2023 Q1
4 quarters
VTRS icon
21
Viatris
VTRS
$20.9B
$15.7M 1.05%
+1,316,469
New +$15.9M
2024 Q1
0 quarters
PCVX icon
22
Vaxcyte
PCVX
$10.3B
$13.5M 0.9%
197,331
-36,508
-16% -$2.53M
2022 Q4
5 quarters
HUM icon
23
Humana
HUM
$51.9B
$12.3M 0.82%
35,532
+33,618
+1,756% +$12.7M
2022 Q2
7 quarters
PTGX icon
24
Protagonist Therapeutics
PTGX
$8.84B
$11.9M 0.79%
411,478
-126,596
-24% -$3.44M
2023 Q2
3 quarters
TARO icon
25
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$11.2M 0.74%
263,541
+7,553
+3% +$318K
2019 Q4
17 quarters
1
2 3

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q1 2024 Portfolio in Review

As of Q1 2024, Eversept Partners held 74 positions worth $1.5B, up 32% from $1.14B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Eversept Partners deployed $95.2M of net new capital in Q1 2024, opening 17 new positions and adding to 21 existing holdings. Its largest new stake was Pfizer: 1,102,042 shares worth $30.6M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 90% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Natera, an estimated $35.6M trimmed.

  • Eversept Partners's largest Q1 2024 buy was Pfizer: 1,102,042 shares worth $30.6M.
  • Eversept Partners added most to GSK in Q1 2024, an estimated $33M increase.
  • Eversept Partners's biggest Q1 2024 reduction was Natera, cutting an estimated $35.6M.
  • Eversept Partners fully exited Immunogen Inc in Q1 2024, selling an estimated $22.2M.
  • Eversept Partners's ten largest holdings make up 63% of its $1.5B portfolio in Q1 2024.
  • Eversept Partners opened 17 new positions and closed 4 in Q1 2024.
  • Eversept Partners's portfolio value rose 32% quarter-over-quarter to $1.5B.

Based on Eversept Partners's 13F filing for Q1 2024, filed 15 May 2024.